img

Global Acute Migraine Medications Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Acute Migraine Medications Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
The global Acute Migraine Medications market size was US$ 2104.4 million in 2024 and is forecast to a readjusted size of US$ 2672.4 million by 2034 with a CAGR of 3.4% during the forecast period 2024-2034.
The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.
In terms of sales (consumption) side, this report focuses on the sales of Acute Migraine Medications by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Acute Migraine Medications market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Acute Migraine Medications market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


GSK
Teva
Pfizer
Novartis
Merck
Sun Pharma
Grunenthal
Endo Pharmaceuticals
By Type
Triptans
NSAIDs
Others
By Application
Drug Stores
Hospital Pharmacies
Sales by Region
North America
United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Acute Migraine Medications in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Acute Migraine Medications manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Acute Migraine Medications sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Acute Migraine Medications Definition
1.2 Market by Type
1.2.1 Global Acute Migraine Medications Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Triptans
1.2.3 NSAIDs
1.2.4 Others
1.3 Market Segment by Application
1.3.1 Global Acute Migraine Medications Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Drug Stores
1.3.3 Hospital Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Acute Migraine Medications Sales
2.1 Global Acute Migraine Medications Revenue Estimates and Forecasts 2018-2034
2.2 Global Acute Migraine Medications Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Acute Migraine Medications Revenue by Region
2.3.1 Global Acute Migraine Medications Revenue by Region (2018-2023)
2.3.2 Global Acute Migraine Medications Revenue by Region (2024-2034)
2.4 Global Acute Migraine Medications Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Acute Migraine Medications Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Acute Migraine Medications Sales Quantity by Region
2.6.1 Global Acute Migraine Medications Sales Quantity by Region (2018-2023)
2.6.2 Global Acute Migraine Medications Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Acute Migraine Medications Sales Quantity by Manufacturers
3.1.1 Global Acute Migraine Medications Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Acute Migraine Medications Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Acute Migraine Medications Sales in 2024
3.2 Global Acute Migraine Medications Revenue by Manufacturers
3.2.1 Global Acute Migraine Medications Revenue by Manufacturers (2018-2023)
3.2.2 Global Acute Migraine Medications Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Acute Migraine Medications Revenue in 2024
3.3 Global Acute Migraine Medications Sales Price by Manufacturers
3.4 Global Key Players of Acute Migraine Medications, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Acute Migraine Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Acute Migraine Medications, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Acute Migraine Medications, Product Offered and Application
3.8 Global Key Manufacturers of Acute Migraine Medications, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Acute Migraine Medications Sales Quantity by Type
4.1.1 Global Acute Migraine Medications Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Acute Migraine Medications Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Acute Migraine Medications Sales Quantity Market Share by Type (2018-2034)
4.2 Global Acute Migraine Medications Revenue by Type
4.2.1 Global Acute Migraine Medications Historical Revenue by Type (2018-2023)
4.2.2 Global Acute Migraine Medications Forecasted Revenue by Type (2024-2034)
4.2.3 Global Acute Migraine Medications Revenue Market Share by Type (2018-2034)
4.3 Global Acute Migraine Medications Price by Type
4.3.1 Global Acute Migraine Medications Price by Type (2018-2023)
4.3.2 Global Acute Migraine Medications Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Acute Migraine Medications Sales Quantity by Application
5.1.1 Global Acute Migraine Medications Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Acute Migraine Medications Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Acute Migraine Medications Sales Quantity Market Share by Application (2018-2034)
5.2 Global Acute Migraine Medications Revenue by Application
5.2.1 Global Acute Migraine Medications Historical Revenue by Application (2018-2023)
5.2.2 Global Acute Migraine Medications Forecasted Revenue by Application (2024-2034)
5.2.3 Global Acute Migraine Medications Revenue Market Share by Application (2018-2034)
5.3 Global Acute Migraine Medications Price by Application
5.3.1 Global Acute Migraine Medications Price by Application (2018-2023)
5.3.2 Global Acute Migraine Medications Price Forecast by Application (2024-2034)
6 North America
6.1 North America Acute Migraine Medications Sales by Company
6.1.1 North America Acute Migraine Medications Revenue by Company (2018-2023)
6.1.2 North America Acute Migraine Medications Sales Quantity by Company (2018-2023)
6.2 North America Acute Migraine Medications Market Size by Type
6.2.1 North America Acute Migraine Medications Sales Quantity by Type (2018-2034)
6.2.2 North America Acute Migraine Medications Revenue by Type (2018-2034)
6.3 North America Acute Migraine Medications Market Size by Application
6.3.1 North America Acute Migraine Medications Sales Quantity by Application (2018-2034)
6.3.2 North America Acute Migraine Medications Revenue by Application (2018-2034)
6.4 North America Acute Migraine Medications Market Size by Country
6.4.1 North America Acute Migraine Medications Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Acute Migraine Medications Revenue by Country (2018-2034)
6.4.3 North America Acute Migraine Medications Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Acute Migraine Medications Sales by Company
7.1.1 Europe Acute Migraine Medications Sales Quantity by Company (2018-2023)
7.1.2 Europe Acute Migraine Medications Revenue by Company (2018-2023)
7.2 Europe Acute Migraine Medications Market Size by Type
7.2.1 Europe Acute Migraine Medications Sales Quantity by Type (2018-2034)
7.2.2 Europe Acute Migraine Medications Revenue by Type (2018-2034)
7.3 Europe Acute Migraine Medications Market Size by Application
7.3.1 Europe Acute Migraine Medications Sales Quantity by Application (2018-2034)
7.3.2 Europe Acute Migraine Medications Revenue by Application (2018-2034)
7.4 Europe Acute Migraine Medications Market Size by Country
7.4.1 Europe Acute Migraine Medications Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Acute Migraine Medications Revenue by Country (2018-2034)
7.4.3 Europe Acute Migraine Medications Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Acute Migraine Medications Sales by Company
8.1.1 China Acute Migraine Medications Sales Quantity by Company (2018-2023)
8.1.2 China Acute Migraine Medications Revenue by Company (2018-2023)
8.2 China Acute Migraine Medications Market Size by Type
8.2.1 China Acute Migraine Medications Sales Quantity by Type (2018-2034)
8.2.2 China Acute Migraine Medications Revenue by Type (2018-2034)
8.3 China Acute Migraine Medications Market Size by Application
8.3.1 China Acute Migraine Medications Sales Quantity by Application (2018-2034)
8.3.2 China Acute Migraine Medications Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Acute Migraine Medications Sales by Company
9.1.1 APAC Acute Migraine Medications Sales Quantity by Company (2018-2023)
9.1.2 APAC Acute Migraine Medications Revenue by Company (2018-2023)
9.2 APAC Acute Migraine Medications Market Size by Type
9.2.1 APAC Acute Migraine Medications Sales Quantity by Type (2018-2034)
9.2.2 APAC Acute Migraine Medications Revenue by Type (2018-2034)
9.3 APAC Acute Migraine Medications Market Size by Application
9.3.1 APAC Acute Migraine Medications Sales Quantity by Application (2018-2034)
9.3.2 APAC Acute Migraine Medications Revenue by Application (2018-2034)
9.4 APAC Acute Migraine Medications Market Size by Region
9.4.1 APAC Acute Migraine Medications Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Acute Migraine Medications Revenue by Region (2018-2034)
9.4.3 APAC Acute Migraine Medications Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Acute Migraine Medications Sales by Company
10.1.1 Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Acute Migraine Medications Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Acute Migraine Medications Market Size by Type
10.2.1 Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Acute Migraine Medications Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Acute Migraine Medications Market Size by Application
10.3.1 Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Acute Migraine Medications Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Acute Migraine Medications Market Size by Country
10.4.1 Middle East, Africa and Latin America Acute Migraine Medications Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Acute Migraine Medications Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 GSK
11.1.1 GSK Company Information
11.1.2 GSK Overview
11.1.3 GSK Acute Migraine Medications Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 GSK Acute Migraine Medications Products and Services
11.1.5 GSK Acute Migraine Medications SWOT Analysis
11.1.6 GSK Recent Developments
11.2 Teva
11.2.1 Teva Company Information
11.2.2 Teva Overview
11.2.3 Teva Acute Migraine Medications Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Teva Acute Migraine Medications Products and Services
11.2.5 Teva Acute Migraine Medications SWOT Analysis
11.2.6 Teva Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Acute Migraine Medications Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Pfizer Acute Migraine Medications Products and Services
11.3.5 Pfizer Acute Migraine Medications SWOT Analysis
11.3.6 Pfizer Recent Developments
11.4 Novartis
11.4.1 Novartis Company Information
11.4.2 Novartis Overview
11.4.3 Novartis Acute Migraine Medications Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Novartis Acute Migraine Medications Products and Services
11.4.5 Novartis Acute Migraine Medications SWOT Analysis
11.4.6 Novartis Recent Developments
11.5 Merck
11.5.1 Merck Company Information
11.5.2 Merck Overview
11.5.3 Merck Acute Migraine Medications Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Merck Acute Migraine Medications Products and Services
11.5.5 Merck Acute Migraine Medications SWOT Analysis
11.5.6 Merck Recent Developments
11.6 Sun Pharma
11.6.1 Sun Pharma Company Information
11.6.2 Sun Pharma Overview
11.6.3 Sun Pharma Acute Migraine Medications Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Sun Pharma Acute Migraine Medications Products and Services
11.6.5 Sun Pharma Acute Migraine Medications SWOT Analysis
11.6.6 Sun Pharma Recent Developments
11.7 Grunenthal
11.7.1 Grunenthal Company Information
11.7.2 Grunenthal Overview
11.7.3 Grunenthal Acute Migraine Medications Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Grunenthal Acute Migraine Medications Products and Services
11.7.5 Grunenthal Acute Migraine Medications SWOT Analysis
11.7.6 Grunenthal Recent Developments
11.8 Endo Pharmaceuticals
11.8.1 Endo Pharmaceuticals Company Information
11.8.2 Endo Pharmaceuticals Overview
11.8.3 Endo Pharmaceuticals Acute Migraine Medications Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Endo Pharmaceuticals Acute Migraine Medications Products and Services
11.8.5 Endo Pharmaceuticals Acute Migraine Medications SWOT Analysis
11.8.6 Endo Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Acute Migraine Medications Value Chain Analysis
12.2 Acute Migraine Medications Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Acute Migraine Medications Production Mode & Process
12.4 Acute Migraine Medications Sales and Marketing
12.4.1 Acute Migraine Medications Sales Channels
12.4.2 Acute Migraine Medications Distributors
12.5 Acute Migraine Medications Customers
13 Market Dynamics
13.1 Acute Migraine Medications Industry Trends
13.2 Acute Migraine Medications Market Drivers
13.3 Acute Migraine Medications Market Challenges
13.4 Acute Migraine Medications Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Acute Migraine Medications Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Triptans
Table 3. Major Manufacturers of NSAIDs
Table 4. Major Manufacturers of Others
Table 5. Global Acute Migraine Medications Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Acute Migraine Medications Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Acute Migraine Medications Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Acute Migraine Medications Revenue Market Share by Region (2018-2023)
Table 9. Global Acute Migraine Medications Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Acute Migraine Medications Revenue Market Share by Region (2024-2034)
Table 11. Global Acute Migraine Medications Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 12. Global Acute Migraine Medications Sales by Region (2018-2023) & (K Units)
Table 13. Global Acute Migraine Medications Sales Market Share by Region (2018-2023)
Table 14. Global Acute Migraine Medications Sales by Region (2024-2034) & (K Units)
Table 15. Global Acute Migraine Medications Sales Market Share by Region (2024-2034)
Table 16. Global Acute Migraine Medications Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 17. Global Acute Migraine Medications Sales Quantity Share by Manufacturers (2018-2023)
Table 18. Global Acute Migraine Medications Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 19. Global Acute Migraine Medications Revenue Share by Manufacturers (2018-2023)
Table 20. Global Acute Migraine Medications Price by Manufacturers 2018-2023 (US$/Unit)
Table 21. Global Key Players of Acute Migraine Medications, Industry Ranking, 2021 VS 2024
Table 22. Global Acute Migraine Medications Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Acute Migraine Medications by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acute Migraine Medications as of 2024)
Table 24. Global Key Manufacturers of Acute Migraine Medications, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Acute Migraine Medications, Product Offered and Application
Table 26. Global Key Manufacturers of Acute Migraine Medications, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Acute Migraine Medications Sales Quantity by Type (2018-2023) & (K Units)
Table 29. Global Acute Migraine Medications Sales Quantity by Type (2024-2034) & (K Units)
Table 30. Global Acute Migraine Medications Sales Quantity Share by Type (2018-2023)
Table 31. Global Acute Migraine Medications Sales Quantity Share by Type (2024-2034)
Table 32. Global Acute Migraine Medications Revenue by Type (2018-2023) & (US$ Million)
Table 33. Global Acute Migraine Medications Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Acute Migraine Medications Revenue Share by Type (2018-2023)
Table 35. Global Acute Migraine Medications Revenue Share by Type (2024-2034)
Table 36. Acute Migraine Medications Price by Type (2018-2023) & (US$/Unit)
Table 37. Global Acute Migraine Medications Price Forecast by Type (2024-2034) & (US$/Unit)
Table 38. Global Acute Migraine Medications Sales Quantity by Application (2018-2023) & (K Units)
Table 39. Global Acute Migraine Medications Sales Quantity by Application (2024-2034) & (K Units)
Table 40. Global Acute Migraine Medications Sales Quantity Share by Application (2018-2023)
Table 41. Global Acute Migraine Medications Sales Quantity Share by Application (2024-2034)
Table 42. Global Acute Migraine Medications Revenue by Application (2018-2023) & (US$ Million)
Table 43. Global Acute Migraine Medications Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Acute Migraine Medications Revenue Share by Application (2018-2023)
Table 45. Global Acute Migraine Medications Revenue Share by Application (2024-2034)
Table 46. Acute Migraine Medications Price by Application (2018-2023) & (US$/Unit)
Table 47. Global Acute Migraine Medications Price Forecast by Application (2024-2034) & (US$/Unit)
Table 48. North America Acute Migraine Medications Revenue by Company (2018-2023) & (US$ Million)
Table 49. North America Acute Migraine Medications Sales Quantity by Company (2018-2023) & (K Units)
Table 50. North America Acute Migraine Medications Sales Quantity by Type (2018-2023) & (K Units)
Table 51. North America Acute Migraine Medications Sales Quantity by Type (2024-2034) & (K Units)
Table 52. North America Acute Migraine Medications Revenue by Type (2018-2023) & (US$ Million)
Table 53. North America Acute Migraine Medications Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Acute Migraine Medications Sales Quantity by Application (2018-2023) & (K Units)
Table 55. North America Acute Migraine Medications Sales Quantity by Application (2024-2034) & (K Units)
Table 56. North America Acute Migraine Medications Revenue by Application (2018-2023) & (US$ Million)
Table 57. North America Acute Migraine Medications Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Acute Migraine Medications Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 59. North America Acute Migraine Medications Revenue by Country (2018-2023) & (US$ Million)
Table 60. North America Acute Migraine Medications Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Acute Migraine Medications Sales Quantity by Country (2018-2023) & (K Units)
Table 62. North America Acute Migraine Medications Sales Quantity by Country (2024-2034) & (K Units)
Table 63. Europe Acute Migraine Medications Sales Quantity by Company (2018-2023) & (K Units)
Table 64. Europe Acute Migraine Medications Revenue by Company (2018-2023) & (US$ Million)
Table 65. Europe Acute Migraine Medications Sales Quantity by Type (2018-2023) & (K Units)
Table 66. Europe Acute Migraine Medications Sales Quantity by Type (2024-2034) & (K Units)
Table 67. Europe Acute Migraine Medications Revenue by Type (2018-2023) & (US$ Million)
Table 68. Europe Acute Migraine Medications Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Acute Migraine Medications Sales Quantity by Application (2018-2023) & (K Units)
Table 70. Europe Acute Migraine Medications Sales Quantity by Application (2024-2034) & (K Units)
Table 71. Europe Acute Migraine Medications Revenue by Application (2018-2023) & (US$ Million)
Table 72. Europe Acute Migraine Medications Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Acute Migraine Medications Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 74. Europe Acute Migraine Medications Revenue by Country (2018-2023) & (US$ Million)
Table 75. Europe Acute Migraine Medications Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Acute Migraine Medications Sales Quantity by Country (2018-2023) & (K Units)
Table 77. Europe Acute Migraine Medications Sales Quantity by Country (2024-2034) & (K Units)
Table 78. China Acute Migraine Medications Sales Quantity by Company (2018-2023) & (K Units)
Table 79. China Acute Migraine Medications Revenue by Company (2018-2023) & (US$ Million)
Table 80. China Acute Migraine Medications Sales Quantity by Type (2018-2023) & (K Units)
Table 81. China Acute Migraine Medications Sales Quantity by Type (2024-2034) & (K Units)
Table 82. China Acute Migraine Medications Revenue by Type (2018-2023) & (US$ Million)
Table 83. China Acute Migraine Medications Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Acute Migraine Medications Sales Quantity by Application (2018-2023) & (K Units)
Table 85. China Acute Migraine Medications Sales Quantity by Application (2024-2034) & (K Units)
Table 86. China Acute Migraine Medications Revenue by Application (2018-2023) & (US$ Million)
Table 87. China Acute Migraine Medications Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Acute Migraine Medications Sales Quantity by Company (2018-2023) & (K Units)
Table 89. APAC Acute Migraine Medications Revenue by Company (2018-2023) & (US$ Million)
Table 90. APAC Acute Migraine Medications Sales Quantity by Type (2018-2023) & (K Units)
Table 91. APAC Acute Migraine Medications Sales Quantity by Type (2024-2034) & (K Units)
Table 92. APAC Acute Migraine Medications Revenue by Type (2018-2023) & (US$ Million)
Table 93. APAC Acute Migraine Medications Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Acute Migraine Medications Sales Quantity by Application (2018-2023) & (K Units)
Table 95. APAC Acute Migraine Medications Sales Quantity by Application (2024-2034) & (K Units)
Table 96. APAC Acute Migraine Medications Revenue by Application (2018-2023) & (US$ Million)
Table 97. APAC Acute Migraine Medications Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Acute Migraine Medications Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 99. APAC Acute Migraine Medications Revenue by Region (2018-2023) & (US$ Million)
Table 100. APAC Acute Migraine Medications Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Acute Migraine Medications Sales Quantity by Region (2018-2023) & (K Units)
Table 102. APAC Acute Migraine Medications Sales Quantity by Region (2024-2034) & (K Units)
Table 103. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Company (2018-2023) & (K Units)
Table 104. Middle East, Africa and Latin America Acute Migraine Medications Revenue by Company (2018-2023) & (US$ Million)
Table 105. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Type (2018-2023) & (K Units)
Table 106. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Type (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America Acute Migraine Medications Revenue by Type (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Acute Migraine Medications Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Application (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America Acute Migraine Medications Revenue by Application (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America Acute Migraine Medications Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Acute Migraine Medications Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Acute Migraine Medications Revenue by Country (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Acute Migraine Medications Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Country (2018-2023) & (K Units)
Table 117. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity by Country (2024-2034) & (K Units)
Table 118. GSK Company Information
Table 119. GSK Description and Overview
Table 120. GSK Acute Migraine Medications Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 121. GSK Acute Migraine Medications Product and Services
Table 122. GSK Acute Migraine Medications SWOT Analysis
Table 123. GSK Recent Developments
Table 124. Teva Company Information
Table 125. Teva Description and Overview
Table 126. Teva Acute Migraine Medications Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 127. Teva Acute Migraine Medications Product and Services
Table 128. Teva Acute Migraine Medications SWOT Analysis
Table 129. Teva Recent Developments
Table 130. Pfizer Company Information
Table 131. Pfizer Description and Overview
Table 132. Pfizer Acute Migraine Medications Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 133. Pfizer Acute Migraine Medications Product and Services
Table 134. Pfizer Acute Migraine Medications SWOT Analysis
Table 135. Pfizer Recent Developments
Table 136. Novartis Company Information
Table 137. Novartis Description and Overview
Table 138. Novartis Acute Migraine Medications Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 139. Novartis Acute Migraine Medications Product and Services
Table 140. Novartis Acute Migraine Medications SWOT Analysis
Table 141. Novartis Recent Developments
Table 142. Merck Company Information
Table 143. Merck Description and Overview
Table 144. Merck Acute Migraine Medications Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 145. Merck Acute Migraine Medications Product and Services
Table 146. Merck Acute Migraine Medications SWOT Analysis
Table 147. Merck Recent Developments
Table 148. Sun Pharma Company Information
Table 149. Sun Pharma Description and Overview
Table 150. Sun Pharma Acute Migraine Medications Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 151. Sun Pharma Acute Migraine Medications Product and Services
Table 152. Sun Pharma Acute Migraine Medications SWOT Analysis
Table 153. Sun Pharma Recent Developments
Table 154. Grunenthal Company Information
Table 155. Grunenthal Description and Overview
Table 156. Grunenthal Acute Migraine Medications Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 157. Grunenthal Acute Migraine Medications Product and Services
Table 158. Grunenthal Acute Migraine Medications SWOT Analysis
Table 159. Grunenthal Recent Developments
Table 160. Endo Pharmaceuticals Company Information
Table 161. Endo Pharmaceuticals Description and Overview
Table 162. Endo Pharmaceuticals Acute Migraine Medications Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 163. Endo Pharmaceuticals Acute Migraine Medications Product and Services
Table 164. Endo Pharmaceuticals Acute Migraine Medications SWOT Analysis
Table 165. Endo Pharmaceuticals Recent Developments
Table 166. Key Raw Materials Lists
Table 167. Raw Materials Key Suppliers Lists
Table 168. Acute Migraine Medications Distributors List
Table 169. Acute Migraine Medications Customers List
Table 170. Acute Migraine Medications Market Trends
Table 171. Acute Migraine Medications Market Drivers
Table 172. Acute Migraine Medications Market Challenges
Table 173. Acute Migraine Medications Market Restraints
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Acute Migraine Medications Product Picture
Figure 2. Global Acute Migraine Medications Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Acute Migraine Medications Market Share by Type in 2024 & 2034
Figure 4. Triptans Product Picture
Figure 5. NSAIDs Product Picture
Figure 6. Others Product Picture
Figure 7. Global Acute Migraine Medications Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 8. Global Acute Migraine Medications Market Share by Application in 2024 & 2034
Figure 9. Drug Stores
Figure 10. Hospital Pharmacies
Figure 11. Acute Migraine Medications Report Years Considered
Figure 12. Global Acute Migraine Medications Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Acute Migraine Medications Revenue 2018-2034 (US$ Million)
Figure 14. Global Acute Migraine Medications Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 15. Global Acute Migraine Medications Sales Quantity 2018-2034 (K Units)
Figure 16. Global Acute Migraine Medications Sales Quantity Market Share by Region (2018-2023)
Figure 17. Global Acute Migraine Medications Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Acute Migraine Medications Sales Quantity YoY (2018-2034) & (K Units)
Figure 19. North America Acute Migraine Medications Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Acute Migraine Medications Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. Europe Acute Migraine Medications Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Acute Migraine Medications Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. China Acute Migraine Medications Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Acute Migraine Medications Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. APAC Acute Migraine Medications Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Middle East, Africa and Latin America Acute Migraine Medications Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Acute Migraine Medications Sales Quantity in 2024
Figure 29. The Top 10 and Top 5 Players Market Share by Acute Migraine Medications Revenue in 2024
Figure 30. Acute Migraine Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 31. Global Acute Migraine Medications Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Acute Migraine Medications Revenue Market Share by Type (2018-2034)
Figure 33. Global Acute Migraine Medications Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Acute Migraine Medications Revenue Market Share by Application (2018-2034)
Figure 35. North America Acute Migraine Medications Revenue Market Share by Company in 2024
Figure 36. North America Acute Migraine Medications Sales Quantity Market Share by Company in 2024
Figure 37. North America Acute Migraine Medications Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Acute Migraine Medications Revenue Market Share by Type (2018-2034)
Figure 39. North America Acute Migraine Medications Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Acute Migraine Medications Revenue Market Share by Application (2018-2034)
Figure 41. North America Acute Migraine Medications Revenue Share by Country (2018-2034)
Figure 42. North America Acute Migraine Medications Sales Quantity Share by Country (2018-2034)
Figure 43. United States Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Acute Migraine Medications Sales Quantity Market Share by Company in 2024
Figure 46. Europe Acute Migraine Medications Revenue Market Share by Company in 2024
Figure 47. Europe Acute Migraine Medications Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Acute Migraine Medications Revenue Market Share by Type (2018-2034)
Figure 49. Europe Acute Migraine Medications Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Acute Migraine Medications Revenue Market Share by Application (2018-2034)
Figure 51. Europe Acute Migraine Medications Revenue Share by Country (2018-2034)
Figure 52. Europe Acute Migraine Medications Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 54. France Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 58. China Acute Migraine Medications Sales Quantity Market Share by Company in 2024
Figure 59. China Acute Migraine Medications Revenue Market Share by Company in 2024
Figure 60. China Acute Migraine Medications Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Acute Migraine Medications Revenue Market Share by Type (2018-2034)
Figure 62. China Acute Migraine Medications Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Acute Migraine Medications Revenue Market Share by Application (2018-2034)
Figure 64. APAC Acute Migraine Medications Sales Quantity Market Share by Company in 2024
Figure 65. APAC Acute Migraine Medications Revenue Market Share by Company in 2024
Figure 66. APAC Acute Migraine Medications Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Acute Migraine Medications Revenue Market Share by Type (2018-2034)
Figure 68. APAC Acute Migraine Medications Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Acute Migraine Medications Revenue Market Share by Application (2018-2034)
Figure 70. APAC Acute Migraine Medications Revenue Share by Region (2018-2034)
Figure 71. APAC Acute Migraine Medications Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 76. India Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity Market Share by Company in 2024
Figure 78. Middle East, Africa and Latin America Acute Migraine Medications Revenue Market Share by Company in 2024
Figure 79. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Acute Migraine Medications Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Acute Migraine Medications Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Acute Migraine Medications Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Acute Migraine Medications Revenue Share by Country (2018-2034)
Figure 85. Brazil Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Acute Migraine Medications Revenue (2018-2034) & (US$ Million)
Figure 90. Acute Migraine Medications Value Chain
Figure 91. Acute Migraine Medications Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed